Absci Corporation
ABSIHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframePart of the healthcare sector, Absci Corporation (ABSI) is listed under Biotechnology. Valued at $1.41B, ABSI is a small-cap name in its sector. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology.
Market Cap
$1.41B
Beta
2.33
P/E (TTM)
—
P/E (Fwd)
-13.32
EPS (TTM)
$-0.83
EPS (Fwd)
$-0.62
ROE
-63.9%
ROA
-37.3%
Cash
$125.7M
Total Debt
$4.4M
Free CF
-$41.5M
52W Change
165.9%
Annual Financials
Cash vs Debt
Absci Corporation holds $125.7M in cash against $4.4M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$41.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -63.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $5.7M (2022) to $2.8M (2025), a 51% decline worth watching.
With a beta above 1.5, ABSI tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, ABSI has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Absci Corporation's trajectory.